CFH and heart failure: Since the landmark PARADIGM-HF1 and DAPA-HF2 trials, heart failure with reduced ejection fraction (HFrEF) guidelines have been updated to incorporate the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan and SGLT2 inhibitors.